India's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the ...

With the rising incidence of cancer in India, AstraZeneca India's breast cancer medicine trastuzumab deruxtecan (sold under ...

Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

Known as fam-trastuzumab deruxtecan but marketed under the brand name Enhertu, it is meant to treat advanced breast cancer that is HR-positive and HER2-low or ultralow, which has not improved ...

The FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs chemotherapy in certain breast cancer patients.

The TROP2-directed ADC will be sold under the brand name Datroway ... following the successful rollout of their HER2 ADC Enhertu. AZ obtained rights to the TROP2 agent in 2020 by paying Daiichi ...

The drug, developed in partnership with Japan-based Daiichi Sankyo, will be marketed under the brand name Datroway ... the first being the blockbuster Enhertu. Per the terms of the partnership ...

The drug, known in development as datopotamab deruxtecan, or Dato-DXd, will be marketed under the brand name Datroway ... come up short compared with Enhertu. The Citeline report also noted ...

Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In 2022, the drug became the first therapy approved for H ...

Market OverviewThe Global Breast Cancer Therapeutics Market  remains one of the most prevalent forms of cancer worldwide, ...